Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
September 10, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
August 28, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
August 21, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
August 20, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024 08:30 ET | Atossa Therapeutics, Inc.
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
July 22, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
July 02, 2024 16:15 ET | Atossa Therapeutics, Inc.
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
June 28, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate...
Atossa_Therapeutics_logo-min.png
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
June 17, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according...